Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New immunotherapy cocktail aims to simplify cancer treatment

NCT ID NCT05661578

Completed Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Nov 03, 2025 · Last updated Jun 23, 2026 · Updated 45 times

Summary

This study tested a fixed-dose combination of two immunotherapy drugs, tiragolumab and atezolizumab, given together as a single infusion every three weeks. The trial enrolled 64 people with advanced solid tumors that express a protein called PD-L1. The main goal was to check the safety and how the drugs move through the body, not to measure how well they fight the cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PD-L1-SELECTED SOLID TUMORS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Asan Medical Center - PPDS

    Seoul, 05505, South Korea

  • C.H. Regional Reina Sofia - PPDS

    Córdoba, 14004, Spain

  • China Medical University Hospital

    Taichung, 40447, Taiwan

  • Chongqing Sanxia Central Hospital

    Chongqing, 404000, China

  • Gazi University Medical Faculty

    Ankara, 06500, Turkey (Türkiye)

  • General Hospital Pula

    Pula, 52000, Croatia

  • Hacettepe Universitesi Tip Fakultesi Hastanesi

    Ankara, 06100, Turkey (Türkiye)

  • Hospital Clinico Universitario de Valencia

    Valencia, 46010, Spain

  • Hospital Regional Universitario de Malaga ? Hospital General

    Málaga, 29010, Spain

  • Hospital Universitario Virgen del Rocio

    Seville, 41013, Spain

  • Hospital del Mar

    Barcelona, 08003, Spain

  • IASO Obstetrics Gynecology Clinic

    Marousi, 151 23, Greece

  • ICO l?Hospitalet ? Hospital Duran i Reynals

    L'Hospitalet de Llobregat, Barcelona, 08908, Spain

  • Inonu University Faculty of Medicine Turgut Ozal Medical Center

    Malatya, 44280, Turkey (Türkiye)

  • Instituto de Investigacion Oncologica Vall dHebron (VHIO) - EPON

    Barcelona, 8035, Spain

  • Klinicki bolnicki centar Zagreb

    Zagreb, 10000, Croatia

  • Medical Oncology Associates

    Spokane, Washington, 99208, United States

  • Medical Park Seyhan Hospital

    Seyhan, 01060, Turkey (Türkiye)

  • Memorial Ankara Hastanesi

    Ankara, 06520, Turkey (Türkiye)

  • Memorial Sisli Private Hospital

    Istanbul, 34385, Turkey (Türkiye)

  • Namik Kemal University

    Alt?nova, 59100, Turkey (Türkiye)

  • National Cancer Center

    Goyang-si, 10408, South Korea

  • National Cheng Kung University Hospital

    Tainan, 70457, Taiwan

  • National Taiwan University Hospital

    Taipei, 10002, Taiwan

  • Oncology Institute of Vojvodina

    Kamenitz, 21204, Serbia

  • START MADRID_Hospital Universiario Fundacion Jimenez Diaz

    Madrid, 28040, Spain

  • START Madrid_Hospital Universitario HM Sanchinarro_CIOCC

    Madrid, 28050, Spain

  • Seoul National University Bundang Hospital

    Seongnam-si, 13605, South Korea

  • St. Luke's Hospital

    Thessaloniki, 552 36, Greece

  • TAIPEI VETERANS GENERAL HOSPITAL, Urology

    Taipei, 11217, Taiwan

  • University General Hospital of Patras

    Pátrai, 265 00, Greece

  • University Hospital Medical Center Bezanijska kosa

    Belgrade, 11080, Serbia

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

tiragolumab and atezolizumab (immunotherapy drugs given together as a fixed-dose combination)

What this could lead to

If successful, this could provide a more convenient way to deliver a promising immunotherapy combination for certain advanced solid tumors.

What could go wrong

This is a small, early-phase study focused on safety and drug levels, not on how well the treatment works. The combination may not prove effective or could cause significant side effects.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PD-L1-SELECTED SOLID TUMORS PD-L1-SELECTED SOLID TUMORS